Plus   Neg

Stock Alert: AC Immune Shares Soar 82% In Premarket

Shares of AC Immune SA (ACIU) are surging over 82% in pre-market today, after the company announced the initiation of the second highest dosing group its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD).

The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group.

ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen platform addressing proteinopathies across neurodegenerative diseases.

The stock has been trading in the range of $4.07 - $10.14 for the past one year, and closed Wednesday's trade at $7.19, up 6 cents or 0.84%. ACIU is currently trading at $13.11, up $5.92 or 82.34% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT